The Surgeon General vs the Marlboro Man: Who Really Won?

Slideshow

The images in this slide set are from an exhibition curated by Alan Blum, MD, at the University of Alabama Gorgas Library (November to December 2013) to commemorate the 50th anniversary of the Surgeon General’s Report on Smoking and Health, released on January 11, 1964 by Dr. Luther Terry.

Recent Videos
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
4 experts are featured in this series.
3 experts in this video
Related Content
The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.

XMT-1660 Earns Fast Track Designation for HER2–Low/Negative Breast Cancer

Roman Fabbricatore
January 12th 2025
Article

The World Health Organization has approved emiltatug ledadotin as XMT-1660’s international nonproprietary name.

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Topical Gel Significantly Improves EGFR Inhibitor-Related Skin Toxicity

Russ Conroy
January 11th 2025
Article

All patients who received HT-001 in the phase 2a CLEER-001 trial showed significant skin toxicity improvements by 6 weeks.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD
December 30th 2024
Podcast

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Roman Fabbricatore
January 10th 2025
Article
Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.

Belzutifan/Cabozantinib Elicits Promising Activity in Clear Cell RCC

Roman Fabbricatore
January 10th 2025
Article

Safety data from the phase 2 LITESPARK-003 trial evaluating belzutifan/cabozantinib in renal cell carcinoma show no treatment-related deaths.